UBS upgraded Fulgent Genetics (FLGT) to Buy from Neutral with a price target of $30, up from $20, after assuming coverage of the name. The firm sees potential for upside in the company’s Precision Diagnostics unit, which represents 60% of total sales, due to share gain opportunities and a more favorable reimbursement landscape. In addition, Fulgent’s Anatomic Pathology segment has started to recover and is no longer dilutive to growth, the analyst tells investors in a research note. UBS sees the company sustaining 10% revenue growth in 2025 and beyond.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FLGT: